Clinical trials: Adenocarcinoma of the Lung
Lung Cancer
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01414595
- Testing
- DNA analysis, DNA methylation analysis, RNA analysis
- Where
- 11 sites in United States
- Volunteers
- 248 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung
A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
Main objectives: To evaluate the benefit of SI-B001+ docetaxel on overall survival (OS) of bidotaxel. To evaluate the benefit of SI-B001+ Docetaxel over Docetaxel's progression-free survival (PFS) based assessment.
- Trial name
- NCT05943795
- Testing
- SI-B001, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 589 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned…
- Conditions
- Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma
- Trial name
- NCT00946712
- Testing
- Bevacizumab, Carboplatin, Cetuximab
- Where
- 798 sites in United States, Mexico
- Volunteers
- 1,333 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that is absorbed by tumor cells. The drug becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00526461
- Testing
- HPPH
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers
Immunotherapy effectiveness and optimal combination strategy in lung cancers with EGFR uncommon and 20ins mutations was unclear.
- Trial name
- NCT06164574
- Testing
- Survival analysis
- Where
- China
- Volunteers
- 627 people
- Sponsor
- Haiquan Chen
Biomarkers, Lung Adenocarcinoma
Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients
This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as…
- Conditions
- Biomarkers, Lung Adenocarcinoma, Pleural Effusion
- Trial name
- NCT07012759
- Testing
- biomarkers
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Fu Jen Catholic University
Non-Small Cell Lung Cancer, Melanoma
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
- Trial name
- NCT02974725
- Testing
- LXH254, LTT462, Trametinib
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung
Because of the effect in the treatment of NSCLC, the capecitabine and erlotinib may compose to a new regimen for NSCLC. Based on the preclinical observation and the confirmed clinical synergistic anti-tumor activity of combined…
- Trial name
- NCT00816868
- Testing
- erlotinib in combination with capecitabine
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer)
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are…
- Conditions
- Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
- Trial name
- NCT05873686
- Testing
- NXP900
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Nuvectis Pharma, Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
This is a prospective, single arm, phase Ib/IIa study. Up to 25 patients will be enrolled into the study (Part A: 2-18; Part B: 7-19).
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor, Metastatic Cancer, Adenocarcinoma of Lung
- Trial name
- AUTOMAN (NCT04770688)
- Testing
- Osimertinib, Anlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Chest Hospital
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer
Neoplasms, Therapy-Associated
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene…
- Trial name
- NCT02283424
- Testing
- Icotinib, chemotherapy (Carboplatin and Docetaxel)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Non-small Cell Lung Cancer, Melanoma
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs.
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT07160335
- Testing
- HLX17, US-sourced Keytruda®
- Where
- 69 sites in United States, China and 2 more
- Volunteers
- 174 people
- Sponsor
- Shanghai Henlius Biotech
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
This phase II trial is studying how well bortezomib works in treating patients with stage IIIB or stage IV lung cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT00118144
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Lung Adenocarcinoma
Identify Prognostic Biomarkers of Lung Cancer
Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.
- Conditions
- Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT05010330
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.
- Conditions
- Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation
- Trial name
- NCT05503667
- Testing
- Furmonertinib, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.